KR850006173A - 3-치환된 2-옥신돌-1-카르복스아미드의 제조방법 - Google Patents

3-치환된 2-옥신돌-1-카르복스아미드의 제조방법 Download PDF

Info

Publication number
KR850006173A
KR850006173A KR1019850001746A KR850001746A KR850006173A KR 850006173 A KR850006173 A KR 850006173A KR 1019850001746 A KR1019850001746 A KR 1019850001746A KR 850001746 A KR850001746 A KR 850001746A KR 850006173 A KR850006173 A KR 850006173A
Authority
KR
South Korea
Prior art keywords
carbon atoms
alkyl
fluoro
chloro
hydrogen
Prior art date
Application number
KR1019850001746A
Other languages
English (en)
Other versions
KR860001873B1 (ko
Inventor
버나드 카딘 사울
Original Assignee
윌리암 데이비스 훈
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리암 데이비스 훈, 화이자 인코포레이티드 filed Critical 윌리암 데이비스 훈
Publication of KR850006173A publication Critical patent/KR850006173A/ko
Application granted granted Critical
Publication of KR860001873B1 publication Critical patent/KR860001873B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

3-치환된 2-옥신돌-1-카르복스아미드의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(II)의 화합물을 일반식 R1-C(=O)-OH의 카르복실산의 활성유도체와 반응시킴을 특징으로 하여, 하기 일반식(I)의 2-옥신돌-1-카르복스아미드 화합물 및 이의 약학적으로 허용되는 염기 부가염을 제조하는 방법.
    상기식에서,
    X는 수소, 플루오로, 클로로, 브로모, 탄소수 1내지 4의 알킬, 탄소수 3내지 7의 사이클로 알킬, 탄소수 1내지 4의 알콕시, 탄소수 1내지 4의 알킬티오, 트리플루오로메틸, 탄소수 1내지 4이 알킬설피닐, 탄소수 1내지 4의 알킬설포닐, 니트로, 페닐, 탄소수 2내지 4의 알카노일, 벤조일, 테노일, 탄소수 2내지 4의 알칼아미도, 벤즈아미도 및 각각의 알킬에 1내지 3개의 탄소를 갖는 N,N-디알킬설파모일 중에서 선택되고,
    Y는 수소, 플루오로, 클로로, 브로모, 탄소수 1내지 4의 알킬, 탄소수 3내지 7의 사이클로알킬, 탄소수 1내지 4의 알콕시, 탄소수 1내지 4의 알킬티오 및 트리플루오로메틸중에서 선택되거나. X 및 Y가 함께는 4,5-,5,6-또는 6,7-메틸렌 디옥시그룹 또는 4,5-,5,6-또는 6,7-에틸렌디옥시 그룹을 나타내거나,
    X 및 Y가 인접한 탄소원자에 부착되는 경우에, 이들은 함게 2가의 라디칼 Z를 형성하고, 여기서 Z는
    (여기서, W는 산소 또는 황이다)중에서 선택되며,
    R1은 탄소수 1내지 6의 알킬, 탄소수 3내지 7의 사이클로알킬, 탄소수 3내지 7의 사이클로알케닐, 페닐, 치환된페닐, 알킬부분의 탄소수가 1내지 3인 페닐알킬, 알킬부분의 탄소수가 1내지 3인 (치환된 페닐)알킬, 알킬부분의 탄소수가 1내지 3인 펜옥시알킬, 알키루분의 탄소수가 1내지 3인(치환된 펜옥시)알킬, 알킬부분의 탄소수가 1내지 3인(티오펜옥시)알킬,나프틸, 바이사이클로-[2.2.1[ 헵탄-2-일, 바이사이클로-[2.2.1]-헵트-5-엔 2-일 및 -(CH2)n-Q-R0중에서 선택되고, 여기에서 치환된 페닐, (치환된 페닐)알킬 및 (치환된 펜옥시)알킬의 치환체는 플루오로, 크롤로, 브로모, 탄소수 1내지 4의 알킬, 탄소수 1내지 4의 알콕시 및 트리푸루오로 메틸중에서 선택되며 ;
    n은 0,1 또는 2이고 ;
    Q는 푸란, 티오펜, 피롤, 피라졸, 아미다졸, 티아졸 이소티아졸, 옥사졸, 이소옥사졸, 1,2,3-티아디아졸, 1,3,4-티아디아졸, 1,2,5-티아디아졸, 테트라하이드로푸란, 테트라하이드로티오펜, 테트라하이드로피란, 테트라하이드로티오피란, 피리딘, 피리미딘, 피라진, 벤조[b]푸란 및 벤조[b]티오펜 중에서 선택된 화합물로 부터 유도된 2가의 라디칼이며 ;
    R0는 수소 또는 탄소수 1내지 3의 알킬이다.
  2. 제1항에 있어서, X 및 Y가 각각, 수소, 플루오로, 클로로, 브로모, 탄소수 1내지 4의 알킬, 탄소수 1내지 4의 알콕시, 탄소수 1내지 4의 알킬티오, 니트로 또는 트리플루오로 메틸이거나 ; X 및 Y가 함께는 4,5-, 5,6-또는 6,7-메틸렌디옥시 그룹을 나타내며 ; R1은 탄소수 1내지 6의 알킬, 탄소수 3내지 7의 사이클로알킬,페닐, 치환된페닐, 알킬부분의 탄소수가 1내지 3인 페닐알킬, 알킬부분의 탄소수 1내지 3인 펜옥시알킬, 알킬부분의 탄소수가 1내지 3인(치환된 펜옥시)알킬, 푸릴, 티에닐, 피롤일, 알킬부분의 탄소수가 1내지 3인 알키푸릴, 알킬부분의 탄소수가 1내지 3인 알킬티에닐, 알킬부분의 탄소수가 1내지 3인 푸릴알킬, 알킬부분의 탄소수가 1내지 3인 티에닐알킬 또는 바이사이클로[2.2.1]헵탄-2-일이고, 여기서 상기의 치환된 페닐 그룹 및 치환된 펜옥시 그룹의 치환체는, 플루오로, 클로로, 브로모, 탄소수1내지 4의 알킬 또는 탄소수 1내지 4의 알콕시인 방법.
  3. 제1항 또는 2항에 있어서, 반응을, 불활성 용매중에서 1내지 4몰 당량의 염기성 시약의 존재하에 일반식 R1-C(=O)-OH의 카르복실산의 활성 유도체 1몰 당량 또는 약간 과량을 사용하여 수행하는 방법.
  4. 제1항 내지 3항중 어느 하나에 있어서. 일반식 R¹-C(=O)-C(=O)-OH의 카르복실산의 활성 유도체가 산할라이드, 일반식 R1-C(=O)-O-C(=O)-R1의 대칭 산 무수물, 일반식R1-C(=O)-O-C(=O)-R3의 혼합무수물, 일반식 R1-C(=O)-O-C(=O)-OR4의 혼합무수물, 일반식 R1-C(=O)-OR4의 알킬에스테르, N-하이드록시 이미드 에스테르, 4-니트로페닐 에스테르, 티오페닐에스테르 또는 2,4,5-트리클로로페닐에스테르이며, 여기에서 R3는 벌키 저급알킬 그룹이고, R4는 저분자량 알킬 그룹인 방법.
  5. 제1항 내지 4항중 어느 하나에 있어서, 공정을 극성 비양성자성 용매중, -10 내지 25℃에서 수행하고 상기의 염기성 시약이 3급아민인 방법.
  6. 제1항내지 5항중 어느 하나에 있어서, X가 수소, 5-클로로, 5-플루오로 또는 5-트리플루오로메틸이고 ; Y는 수소, 6-클로로, 6-플루오로 또는 6-트리플루오로메틸이며 ; R1이 벤질, 2-푸릴, 2-티에닐, (2-푸릴)메틸 또는 (2-티에닐)메틸인 방법.
  7. 제6항에 있어서, X가 5-크롤로이고, Y 가 수소이며 R1이 2-티에닐인 방법
  8. 제 6항에 있어서, X가 5-플루오로이고, Y가 6-클로로이며, R1이 조질인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850001746A 1984-03-19 1985-03-18 3-치환된 2-옥신돌-1-카르복스아미드의 제조방법 KR860001873B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59065984A 1984-03-19 1984-03-19
US590659 1984-03-19
US590,659 1984-03-19
US684,634 1984-12-21
US06/684,634 US4556672A (en) 1984-03-19 1984-12-21 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents

Publications (2)

Publication Number Publication Date
KR850006173A true KR850006173A (ko) 1985-10-02
KR860001873B1 KR860001873B1 (ko) 1986-10-24

Family

ID=27080909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850001746A KR860001873B1 (ko) 1984-03-19 1985-03-18 3-치환된 2-옥신돌-1-카르복스아미드의 제조방법

Country Status (36)

Country Link
US (1) US4556672A (ko)
EP (1) EP0156603B1 (ko)
JP (1) JPH04235165A (ko)
KR (1) KR860001873B1 (ko)
AT (1) ATE45731T1 (ko)
AU (1) AU549927B2 (ko)
BG (1) BG60347B2 (ko)
CA (2) CA1251441A (ko)
CS (1) CS249539B2 (ko)
CY (1) CY1668A (ko)
DE (1) DE3572481D1 (ko)
DK (1) DK162090C (ko)
EG (1) EG17795A (ko)
ES (1) ES8603408A1 (ko)
FI (2) FI82042C (ko)
GR (1) GR850668B (ko)
HK (1) HK78392A (ko)
HU (1) HU196178B (ko)
IE (1) IE57743B1 (ko)
IL (3) IL85130A (ko)
LV (1) LV5618A3 (ko)
MA (1) MA20380A1 (ko)
MY (1) MY101987A (ko)
NL (1) NL940025I2 (ko)
NO (1) NO165799C (ko)
NZ (2) NZ224134A (ko)
OA (1) OA07966A (ko)
PH (2) PH21323A (ko)
PL (1) PL145951B1 (ko)
PT (1) PT80117B (ko)
RO (1) RO90952B (ko)
SI (1) SI8510440A8 (ko)
SU (1) SU1445556A3 (ko)
UA (1) UA6343A1 (ko)
YU (1) YU43870B (ko)
ZW (1) ZW4785A1 (ko)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE63543T1 (de) * 1984-02-07 1991-06-15 Pfizer 2-oxindolzwischenprodukte.
US4686224A (en) * 1984-10-31 1987-08-11 Pfizer Inc. Oxindole antiinflammatory agents
EP0208510B1 (en) * 1985-07-09 1991-09-11 Pfizer Inc. 1-substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents
US4678802A (en) * 1985-07-09 1987-07-07 Pfizer Inc. 1-acylcarbamoyloxindole-3-carboxamides as antiinflammatory agents
GB8623819D0 (en) * 1986-10-03 1986-11-05 Glaxo Group Ltd Heterocyclic compounds
RO105052B1 (en) * 1987-02-02 1994-12-01 Pfizer Producing process for the crystalline sodium salt, anhydre, of 5-chlorine-3-(2-tenoil)-2-oxindol-1-carboxamide
US4885370A (en) * 1987-03-11 1989-12-05 Pfizer Inc. Synthetic method for indol-2(3H)-ones
US4761485A (en) * 1987-03-11 1988-08-02 Pfizer Inc. Synthetic method for indol-2(3H)-ones
GB8720693D0 (en) * 1987-09-03 1987-10-07 Glaxo Group Ltd Chemical compounds
DE3803775A1 (de) * 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4853409A (en) * 1988-04-13 1989-08-01 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
SK590689A3 (en) * 1988-10-18 1996-03-06 Pfizer 3-aryl-2-oxindole-1-carboxamides and method of their preparation
DE68923673T2 (de) * 1988-10-18 1996-01-18 Pfizer Prodrogen von antiinflammatorischen 3-Acyl-2-oxindol-1-carboxamiden.
HU215112B (hu) * 1989-01-10 1998-12-28 Pfizer Inc. Eljárás gyulladáscsökkentő 1-heteroaril-3-acil-2-oxindol-származékok előállítására
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
US5300655A (en) * 1989-04-18 1994-04-05 Pfizer Inc. 2-carboxy-thiophene derivatives
US5059693A (en) * 1989-10-06 1991-10-22 Pfizer Inc. Process for making 3-aroyl-2-oxindole-1-carboxamides
IL95880A (en) * 1989-10-13 1995-12-31 Pfizer Use of 3-Transformed History of 2-Oxindole for the Preparation of Pharmaceuticals for Inhibition of Interlaukio-1 Biosynthesis
WO1991009598A1 (en) * 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
US5008283A (en) * 1990-03-19 1991-04-16 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
US5006547A (en) * 1990-03-19 1991-04-09 Pfizer Inc. Tenidap as an inhibitor of the release of elastase by neutrophils
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
US5122534A (en) * 1991-02-08 1992-06-16 Pfizer Inc. Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
DE4111305C2 (de) * 1991-04-08 1994-12-01 Mack Chem Pharm Pharmazeutische Zubereitung zur rektalen Applikation, die ein 2-Oxindol-l-carboxamid-derivat enthält
DE4111306C2 (de) * 1991-04-08 1994-06-01 Mack Chem Pharm Pharmazeutische Zubereitungen, die ein 2-Oxindol-l-carboxamid-derivat enthalten und zur Injektion bestimmt sind
US5166401A (en) * 1991-06-25 1992-11-24 Pfizer Inc Intermediates for 5-fluoro-6-chlorooxindole
US5210212A (en) * 1991-06-25 1993-05-11 Pfizer Inc Process for 5-fluoro-6-chlorooxindole
TW438798B (en) * 1992-10-07 2001-06-07 Pfizer 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions
US5288743A (en) * 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
US5298522A (en) * 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
CN1116822A (zh) * 1993-01-22 1996-02-14 美国辉瑞有限公司 6-氯-5-氟-3-(2-噻吩甲酰)-2-羟吲哚-1-羰酰胺的赖氨酸盐
US5270331A (en) * 1993-01-26 1993-12-14 Pfizer, Inc. Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides
ATE145206T1 (de) * 1993-02-09 1996-11-15 Pfizer Oxindol 1-(n-(alkoxycarbonyl)>carboxamide und 1- (n-carboxamido>carboxamide als antiinflammatorische wirkstoffe
ES2076106B1 (es) * 1993-08-26 1996-06-16 Pfizer Composiciones farmaceuticas a base de 2-oxindol-1-carboxamidas 3-sustituidas
US5449788A (en) * 1994-01-28 1995-09-12 Catalytica, Inc. Process for preparing 2-oxindole-1-carboxamides
EP0679396A1 (en) * 1994-03-02 1995-11-02 Pfizer Inc. Use of 3-substituted-2-oxidole-1-carboxamides for the manufacture of a medicament in the treatment and prevention of ischemia induced myocardial injury and cytokine mediated myocardial injury
US6469181B1 (en) 1995-01-30 2002-10-22 Catalytica, Inc. Process for preparing 2-oxindoles and N-hydroxy-2-oxindoles
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US6051588A (en) * 1995-04-19 2000-04-18 Nitromed Inc Nitroso esters of β-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
WO1997022605A1 (en) * 1995-12-19 1997-06-26 Pfizer Inc. Stable, long acting salts of indole derivatives for the treatment of joint diseases
HUP9600855A3 (en) * 1996-04-03 1998-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing tenidap
EP0826685A1 (en) * 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
DK1157019T3 (da) * 1998-12-17 2003-07-14 Hoffmann La Roche 4-alkenyl- (og alkynyl-)oxindoler som inhibitorer af cyklinafhængige kinaser, især CDK2
AU760039B2 (en) 1998-12-17 2003-05-08 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of JNK protein kinases
WO2000035921A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
IT1308633B1 (it) 1999-03-02 2002-01-09 Nicox Sa Nitrossiderivati.
JP2003512396A (ja) * 1999-10-26 2003-04-02 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター インドリン化合物を投与することを含む脱毛症の処置方法
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
IT1318673B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Farmaci per le disfunzioni sessuali.
IT1318674B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Faramaci per l'incontinenza.
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
WO2010129819A2 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN102911105B (zh) * 2012-11-12 2013-12-04 辽宁科技大学 一种3-芳酰基吲哚化合物的合成方法
CA2981066A1 (en) * 2015-03-31 2016-10-06 Monsanto Technology Llc Processes for the preparation of 2-thiophenecarbonyl chloride
US10537552B2 (en) 2015-05-05 2020-01-21 Carafe Drug Innovation, Llc Substituted 5-hydroxyoxindoles and their use as analgesics and fever reducers
AU2017238056A1 (en) 2016-03-24 2018-10-04 Monsanto Technology Llc Processes for the preparation of heteroaryl carboxylic acids

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125443C (ko) * 1963-06-06
US3462450A (en) * 1966-06-29 1969-08-19 Merck & Co Inc Chemical compounds
GB1158532A (en) * 1967-01-05 1969-07-16 Centre Nat Rech Scient 2-Oxoindoline-3-Carboxylic Acids and Esters thereof
US3519592A (en) * 1967-04-18 1970-07-07 Smithkline Corp Indole compounds
US3631177A (en) * 1967-04-18 1971-12-28 Smith Kline French Lab 3-phenacyl-2-oxoindolines
BE714717A (ko) * 1967-05-12 1968-09-30
FR7337M (ko) * 1968-01-11 1969-10-13
BE756447A (fr) * 1969-10-15 1971-03-22 Pfizer Oxindolecarboxamides
US3767653A (en) * 1971-06-28 1973-10-23 Squibb & Sons Inc Thiazines
US3749731A (en) * 1971-07-08 1973-07-31 Warner Lambert Co 2-oxo-n-(2-thiazolyl)-3-indoline-carboxamide
DE2306374A1 (de) * 1973-02-09 1974-08-15 Bayer Ag Neue 3-substituierte 2-oxo-4-hydroxy1,2,3,4-tetrahydrochinazolin-4-carbonsaeureamide
US4012394A (en) * 1973-02-16 1977-03-15 Labaz Indole derivatives
DE2314242A1 (de) * 1973-03-22 1974-09-26 Bayer Ag Neue 3-substituierte 2-oxo-4-hydroxy1,2,3,4-tetrahydrochinazolin-4-carbonsaeurehydrazide
US3975531A (en) * 1973-10-02 1976-08-17 A. H. Robins Company, Incorporated 4-(5- And 7-)benzoylindolin-2-ones and pharmaceutical uses thereof

Also Published As

Publication number Publication date
US4556672A (en) 1985-12-03
JPH0561269B2 (ko) 1993-09-06
SI8510440A8 (sl) 1996-06-30
FI82042B (fi) 1990-09-28
RO90952A (ro) 1987-02-27
NO851054L (no) 1985-09-20
RO90952B (ro) 1987-03-01
NL940025I1 (nl) 1995-02-01
IL85130A (en) 1988-07-31
PT80117B (pt) 1987-10-20
ATE45731T1 (de) 1989-09-15
ES541372A0 (es) 1985-12-16
OA07966A (fr) 1987-01-31
FI894540A (fi) 1989-09-26
ES8603408A1 (es) 1985-12-16
SU1445556A3 (ru) 1988-12-15
FI894540A0 (fi) 1989-09-26
FI82449C (fi) 1991-03-11
CA1251441A (en) 1989-03-21
LV5618A3 (lv) 1994-05-10
DK121385A (da) 1985-09-20
IL85130A0 (en) 1988-06-30
ZW4785A1 (en) 1985-06-19
NZ211486A (en) 1988-10-28
DK162090C (da) 1992-02-24
CA1288422C (en) 1991-09-03
GR850668B (ko) 1985-07-16
MY101987A (en) 1992-02-29
UA6343A1 (uk) 1994-12-29
CY1668A (en) 1993-05-14
PT80117A (en) 1985-04-01
HU196178B (en) 1988-10-28
EP0156603B1 (en) 1989-08-23
PH21470A (en) 1987-10-28
NO165799B (no) 1991-01-02
KR860001873B1 (ko) 1986-10-24
DK162090B (da) 1991-09-16
DE3572481D1 (en) 1989-09-28
IE57743B1 (en) 1993-03-24
JPH04235165A (ja) 1992-08-24
FI851069L (fi) 1985-09-20
NZ224134A (en) 1988-10-28
AU549927B2 (en) 1986-02-20
DK121385D0 (da) 1985-03-18
IL74631A0 (en) 1985-06-30
PH21323A (en) 1987-09-28
NO165799C (no) 1991-04-10
HK78392A (en) 1992-10-23
YU44085A (en) 1988-02-29
NL940025I2 (nl) 2000-01-03
FI851069A0 (fi) 1985-03-18
IE850684L (en) 1985-09-19
BG60347B2 (bg) 1994-09-30
EP0156603A3 (en) 1986-02-12
FI82042C (fi) 1991-01-10
IL74631A (en) 1988-07-31
AU4005985A (en) 1985-09-26
EG17795A (en) 1990-08-30
FI82449B (fi) 1990-11-30
MA20380A1 (fr) 1985-10-01
PL252434A1 (en) 1985-12-03
PL145951B1 (en) 1988-12-31
EP0156603A2 (en) 1985-10-02
YU43870B (en) 1989-12-31
HUT37398A (en) 1985-12-28
CS249539B2 (en) 1987-03-12

Similar Documents

Publication Publication Date Title
KR850006173A (ko) 3-치환된 2-옥신돌-1-카르복스아미드의 제조방법
KR870004981A (ko) 헤테로시클릭 옥소프탈라지닐 아세트산의 제조방법
KR850005824A (ko) 1,3-이치환된 옥시인돌 화합물의 제조방법
SE7908443L (sv) Heterocykliska foreningar
DK276985D0 (da) Benzofuranderivat og farmaceutisk praeparat indeholdende en saadan forbindelse
PH22981A (en) N,3-disubstituted 2-oxindole 1-carboxamides as analgesic and antiinflammatory agents
KR930701420A (ko) 혈당저하제로서의 하이드록시우레아 유도체
KR830007597A (ko) 3-아릴-5-이소티아졸 유도체의 제조방법
KR920004394A (ko) 티에노디아제핀 이의 제조방법 및 paf-길항 활성을 지닌 약제학적 조성물로서의 이의 용도
KR850006174A (ko) 2-옥스인돌-1-카복스아미드의 제조방법
ES8604554A1 (es) Procedimiento para preparar acidos aroil-benzofuran y benzotiofen-aceticos y propionicos
KR960037655A (ko) 알츠하이머병 치료용 약제
SE7705310L (sv) Kinazolinderivat
KR860002505A (ko) 2-옥스인돌 유도체의 제조방법
Fringuelli et al. Electronic transmission of substituent effects through the pyrrole ring: Ionization constants of some 4-and 5-substituted-2-pyrrolcarboxylic acids
CO4440625A1 (es) Derivados de acido 2-amino-2-(2-carboxicilopropil)acetico y procedimiento para su preparacion
KR850008154A (ko) N, 3-이치환된 2-옥시인돌-1-카복사마이드의 제조방법
KR890009888A (ko) 헤테로시클릭 옥소프탈라지닐 아세트산
KR890701095A (ko) 생물학적 활성 화합물
KR860008983A (ko) 4- 벤조일-1- 알킬(알켄일) 피라졸의 제조방법
ES470213A1 (es) Un procedimiento para la preparacion de nuevos derivados de acido pirrol-1-carboxilico
KR890005126A (ko) 할로알킬 티아졸의 제조방법 및 이 방법으로 제조한 할로알킬 티아졸
FI862570A0 (fi) Nya aromatiska foereningar, deras ramstaellning och anvaendning.
KR850008169A (ko) 1-헤테로아릴-4-아릴-피라졸린-5-온의 제조방법
FI822692A0 (fi) Icke-steroidala foereningar saosom anti-inflammatoriska och smaertstillande medel

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031009

Year of fee payment: 18

LAPS Lapse due to unpaid annual fee